ATAI生命科学公司第四季度每股收益$(0.24)未达预期$(0.15)

财报速递
17 Mar
ATAI生命科学公司(纳斯达克股票代码:ATAI)报告季度每股亏损为$(0.24),未达到分析师预测的$(0.15),低于预期60%。与去年同期每股亏损$(0.12)相比,下降了100%。

以上内容来自Benzinga Earnings专栏,原文如下:

ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.15) by 60 percent. This is a 100 percent decrease over losses of $(0.12) per share from the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10